C4 Therapeutics (CCCC) Enterprise Value (2020 - 2026)

C4 Therapeutics' Enterprise Value history runs 8 years deep, the most recent figure standing at -$235.7 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 40.92% year-over-year to -$235.7 million; the TTM figure through Mar 2026 stood at -$235.7 million (down 40.92% YoY), while the FY2025 annual figure was -$248.5 million, down 1.48% from the prior year.
• Enterprise Value for Q1 2026 stood at -$235.7 million, up from -$248.5 million in the prior quarter.
• The five-year high for Enterprise Value was -$130.5 million in Q4 2023, with the low at -$307.8 million in Q2 2022.
• The 5-year median for Enterprise Value is -$235.7 million (2026), against an average of -$221.6 million.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value soared 47.72% in 2023, then slumped 87.62% in 2024.
• C4 Therapeutics' Enterprise Value stood at -$249.7 million in 2022, then surged by 47.72% to -$130.5 million in 2023, then plunged by 87.62% to -$244.9 million in 2024, then retreated by 1.48% to -$248.5 million in 2025, then gained by 5.18% to -$235.7 million in 2026.
• Business Quant data shows CCCC's Enterprise Value at -$235.7 million in Q1 2026, -$248.5 million in Q4 2025, and -$136.5 million in Q3 2025.